Pharma Focus Asia

Shanghai Genechem Co., Ltd. (Genechem) announces global collaboration on bispecific antibodies

Thursday, April 08, 2021

Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to the discovery of new drug targets and the development of new therapeutic products, today announced the conclusion of a global collaboration with I-Mab, a company global bio-pharmaceutical listed on Nasdaq, to ​​develop and market multiple bispecific antibodies (BsAb) based on the monoclonal antibody developed by Genechem and the antibodies selected by I-MAB.

"This collaboration is the first in a long series that will take advantage of Genechem's Good Research Practices (GRP) and CHAMP antibody discovery platform, its robust bioinformatics database, as well as the expertise in developing synergistic partners, in order to provide globally competitive assets based on innovative targets. We are excited to collaborate with I-Mab, a global leader in oncology and antibody development, to bring more products to meet the unmet clinical needs of patients in China and in the world, ”commented Yueqiong Cao, founder and CEO of Genechem.

Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024